Management of Factor V Leiden

Asymptomatic Carriers

• The American College of Medical Genetics recommends avoiding combined oral contraceptives in women with Factor V Leiden, as the combination increases thrombotic risk 30-fold compared to 4-fold with oral contraceptives alone 1
• Alternative contraceptive methods should be considered in women with Factor V Leiden 1

Situational Prophylaxis

• The American College of Chest Physicians recommends providing prophylactic anticoagulation during high-risk scenarios such as surgery and trauma, regardless of Factor V Leiden status 2, 3, 4, 5, 6
• Prophylactic anticoagulation should also be used during prolonged immobilization 2, 3, 4, 5, 6
• For long-distance travel, frequent ambulation, calf exercises, aisle seating, and properly fitted below-knee graduated compression stockings (15-30 mmHg at ankle) are recommended 1

Pregnancy and Postpartum Management

• The American College of Obstetricians and Gynecologists recommends clinical surveillance only throughout pregnancy for pregnant women who are heterozygous for Factor V Leiden without a family history of VTE 7
• For pregnant women with a family history of VTE in a first-degree relative, consider prophylactic LMWH or UFH throughout the antepartum period 7
• Postpartum, provide prophylactic- or intermediate-dose LMWH, or vitamin K antagonists (INR 2.0-3.0) for 6 weeks in women with a family history of VTE 7

Management After First VTE

• The International Society on Thrombosis and Haemostasis recommends treating the first acute thrombosis according to standard VTE guidelines (therapeutic anticoagulation with LMWH bridged to warfarin or direct oral anticoagulants) 1
• Base decisions on individualized risk assessment, balancing VTE recurrence risk against bleeding risk 1
• For provoked VTE, standard 3-6 months of anticoagulation is recommended 7
• For unprovoked VTE, consider extended or indefinite anticoagulation, particularly in homozygotes or those with additional thrombophilias 1

Testing Recommendations

• The National Society of Genetic Counselors recommends testing for Factor V Leiden in individuals with a strong family history of thrombotic disease, or in those who have experienced venous thrombosis at a young age or in unusual sites 2, 3, 4, 5, 6
• Test for prothrombin G20210A mutation in all Factor V Leiden-positive patients, as this combination significantly increases thrombotic risk 1, 2, 4

Key Clinical Pitfalls

• The American College of Medical Genetics recommends against screening the general population or asymptomatic women before starting oral contraceptives for Factor V Leiden 2, 3, 4, 5, 6
• Do not withhold standard VTE prophylaxis during surgery or hospitalization based on unknown Factor V Leiden status 2, 3, 4, 5, 6

Venous Thromboembolism Risk with Combined Hormonal Contraceptives in Heterozygous Factor V Leiden

Baseline Incidence

• In women younger than 44 years, the baseline incidence of venous thromboembolism (VTE) is approximately 5 events per 100,000 woman‑years. 8

Risk Associated with Combined Hormonal Contraceptives (CHC)

• Use of combined hormonal contraceptives (including oral pills, patches, and vaginal rings) increases VTE risk about 4‑fold compared with baseline in the general female population. 8

Synergistic Risk in Factor V Leiden Heterozygotes

• In women who are heterozygous for Factor V Leiden, concurrent use of CHC raises the VTE risk to ≈30‑fold higher than baseline. 8

Absolute Mortality Impact

• The above relative increase corresponds to an absolute VTE‑related mortality of ~15 deaths per million woman‑years for Factor V Leiden carriers on CHC, versus ~4 deaths per million woman‑years for non‑carriers using CHC alone. 8

Pharmacologic Equivalence of the NuvaRing

• The NuvaRing releases ethinyl estradiol (15 µg) and etonogestrel (120 µg), making it a combined hormonal contraceptive with thrombotic risk comparable to oral contraceptive pills. 9

Clinical Pitfalls to Avoid

• Do not assume the vaginal ring is safer than oral contraceptives merely because it delivers a lower systemic estrogen dose; the thrombotic risk remains comparable. 9
• Do not screen the general population for Factor V Leiden before prescribing CHC; however, if a patient’s Factor V Leiden status is already known, clinicians should avoid CHC in that individual. 8
• While withholding effective contraception can increase pregnancy rates (and pregnancy itself carries VTE risk), the 30‑fold increased VTE risk with CHC in Factor V Leiden carriers outweighs these concerns, supporting the use of safer alternatives. 8